ClinicalTrials.gg
CompletedNCT04034901DACREUpdated Aug 15, 2024

Study of Physiological Signals During and After COPD Exacerbations

An interventional study of Monitoring of cardiorespiratory parameters with BORA Band in COPD and COPD Exacerbation, sponsored by Biosency. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Biosency · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.

Enrollment
208th of 286
42 · median 138
Started
2021
with 20 others
No phase
158 of 406
37 open now
Registered
253rd of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 208th largest by enrollment of the 286 interventional ones that give a count, is one of 21 that started in 2021, is one of 158 with no phase, and was the 253rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, or all of them as a file.
02

Study summary

Background : Acute exacerbations of COPD (Chronic Obstructive Pulmonary Disease) are frequent events in the course of the disease and they can deteriorate the respiratory function of the patients, impact their quality of life and even potentially threaten their life. It is therefore crucial to prevent these exacerbations from occurring.

Aim of the study : Investigate how cardiorespiratory parameters of COPD patients differ between exacerbation phases and their nominal state in order to identify predictors of COPD exacerbations.

Study design : Patients admitted at one of the investigation centers on a suspicion of COPD exacerbation will be enrolled on a voluntary basis. Enrolled patients' cardiorespiratory parameters will be monitored with a connected wrist-worn pulse oximeter (BORA Band) during the hospitalisation phase and one month after they have been discharged.

Setting : 4 investigative centers across Brittany

Patients : 50 patients will be enrolled in the study

03

Conditions studied

  • COPD
  • COPD Exacerbation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient known or suspected to suffer from
  • patient admitted in pulmonology unit for COPD exacerbation
  • patient accepting to use BORA Band during and after hospitalization
  • patient accepting to be followed by the partner health care provider for this study (Air de Bretagne)
  • patient able to understand French and express their
  • patient affiliated to social security

Exclusion criteria

Exclusion Criteria:

  • patient is intubated
  • patient already followed by a health care provider other than Air de Bretagne
  • investigator assesses that the patient will have difficulties following the protocol
  • patient already enrolled in another interventional study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Monitoring of cardiorespiratory parameters

    Monitoring of cardiorespiratory parameters with BORA Band

    Device: Monitoring of cardiorespiratory parameters with BORA Band

Interventions

  • DeviceMonitoring of cardiorespiratory parameters with BORA Band

    The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements : * Activity * Step count * Heart rate * Respiratory rate * Skin temperature * SpO2

06

What researchers measure

Primary outcomes

  1. Variation of heart rate during and after a COPD acute exacerbation

    Average heart rate in beats per minute during and after COPD exacerbation will be assessed thanks to a wrist-worn connected pulse oximeter

    Time frame: 2 months

  2. Variation of respiratory rate during and after a COPD acute exacerbation

    Average respiratory rate in cycles per minute during and after COPD exacerbation will be assessed thanks to a wrist-worn connected pulse oximeter

    Time frame: 2 months

  3. Variation of SpO2 during and after a COPD acute exacerbation

    Average SpO2 in percent during and after COPD exacerbation will be assessed thanks to a wrist-worn connected pulse oximeter

    Time frame: 2 months

  4. Variation of skin temperature during and after a COPD acute exacerbation

    Average skin temperature in celcius during and after COPD exacerbation will be assessed thanks to a wrist-worn connected pulse oximeter

    Time frame: 2 months

  5. Variation of patient activity during and after a COPD acute exacerbation

    Average patient activity measured in activity duration per day during and after COPD exacerbation will be assessed thanks to a wrist-worn connected pulse oximeter

    Time frame: 2 months

Secondary outcomes

  1. Connected wrist-worn pulse oximeter adherence

    The mean duration of bora band utilization will be measured (mean number of days and mean number of hours per day)

    Time frame: 2 months

  2. Patient satisfaction

    the patient satisfaction with the connected wrist-worn pulse oximeter will be assessed using a series of yes or no questions about the comfort, the acceptability, the ease of use and the size of the device.

    Time frame: 2 months

07

Study locations

1 site
  • Chru Pontchaillou
    Rennes, 35000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2024, 35 months.

Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 35 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 26, 2019
StartActual
Feb 19, 2021
Primary completionActual
Feb 6, 2024
CompletionActual
Feb 6, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04034901
Lead sponsor
Biosency
Collaborators
Slb Pharma, Air de Bretagne, Rennes University Hospital, Centre Hospitalier Bretagne Atlantique, Centre Hospitalier de Saint-Malo, Centre Hospitalier de Saint-Brieuc
Responsible party
Sponsor
First posted
Jul 26, 2019
Start date
Feb 19, 2021
Primary completion
Feb 6, 2024
Completion
Feb 6, 2024
Last update
Aug 15, 2024

Study contacts

Graziella Brinchault, M.D.
principal investigator · CHU Rennes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion